Data Mining Identifies CCN2 and THBS1 as Biomarker Candidates for Cardiac Hypertrophy

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Biomarker Discovery

Background:

• Cardiac hypertrophy is a significant risk factor for heart failure.
• Understanding the molecular mechanisms of cardiac hypertrophy is crucial for developing effective treatments.
• Existing models may not fully capture the complexity of human hypertrophic cardiomyopathy.

Purpose of the Study:

• To compare gene expression profiles between an in vitro stem-cell-based cardiac hypertrophy model and human hypertrophic heart biopsies.
• To identify and validate novel biomarkers for cardiac hypertrophy.
• To elucidate the molecular pathways involved in cardiac hypertrophy development.

Main Methods:

• Gene expression analysis (RNA sequencing) of endothelin-1-treated stem cells and human cardiac biopsies.
• Validation of differentially expressed genes (DEGs) and corresponding proteins using ELISA and Western blot.
• Protein-interaction network analysis and Gene Ontology (GO)-enrichment analysis.

Main Results:

• Twenty-five overlapping differentially expressed genes (DEGs) were identified between the in vitro model and human samples.
• Significant overexpression of biomarkers including CCN2, THBS1, NPPA, and NPPB was observed at both gene and protein levels.
• CCN2 emerged as a central node in protein-interaction networks, suggesting its critical role in cardiac hypertrophy.

Conclusions:

• The study highlights significant similarities between endothelin-1-stimulated stem cell-derived cardiomyocytes and human hypertrophic cardiac tissue.
• Novel putative biomarkers for cardiac hypertrophy were identified and validated at the protein level.
• These findings support further investigation into the clinical utility of identified biomarkers for diagnosing and managing cardiac hypertrophy.